• Ana Pilar Javierre Miranda, Coro Sánchez Hernández, Susana Martín Martín, Pablo Aldaz Herce, José Javier Gómez Marco, Germán Schwarz Chavarri, Cristina García Iglesias, M Isabel Gutiérrez Pérez, M Luisa Morató Agustí, and Grupo de Prevención de Enfermedades Infecciosas del PAPPS.
• Medicina Familiar y Comunitaria, Centro de Salud Avenida de Aragón, SERMAS, Madrid, España. Electronic address: ajavierre@iies.es.
• Aten Primaria. 2024 Nov 1; 56 Suppl 1: 103129103129.

AbstractVaccination throughout life is the best way to prevent infectious diseases and improve people's quality of life. As health professionals we must know the vaccine indications and guidelines as if they were any other treatment. In the updates for this year 2024, we continue to focus on the most relevant developments in terms of indications, changes in vaccination guidelines, new vaccines incorporated into the adult calendar and even anticipating the next vaccines to be incorporated in a short period of time. We continue to insist on remembering the specific indications in risk groups, whether due to chronic diseases or immunocompromise. They are very relevant groups in which to review and complete their vaccination schedule. Nor should we forget about vaccination during pregnancy and for health workers, we must protect ourselves to protect. We have extended the chapter of vaccination for travelers, due to increasing numbers in our Primary Care consultations. And we have added a few touches of the «One Health» approach, focusing on vaccination as a tool to improve population health and contribute to the reduced use of antibiotics and thereby avoid bacterial resistance. We have tried to summarize a large part of the document in the form of tables so that it is an agile and easy-to-consult instrument in our daily care work and we do not forget to review and complete, if necessary, the vaccination schedule of all our patients. Although we focus on adults, due to the novelty and relevance in terms of reducing the burden of disease in infants, we have included a section on immunoprevention against respiratory syncytial virus with monoclonal antibodies and its indications for the next 2024-2025 season.Copyright © 2024 The Authors. Publicado por Elsevier España S.L.U. All rights reserved.

20 keywords...

hide…